“…Typically, the dose-limiting organ in targeted radionuclide therapy (TRT) is the bone marrow (Sgouros, 2007;Sgouros et al, 2000). Auger-electron emitters are attractive candidate radionuclides in TRT of disseminated diseases (and micrometastasis) due to a vanishing cross-irradiation effect which spares healthy cells in the vicinity of the targeted cells (Fischer et al, 2008;Kassis, 2011Kassis, , 2004Yasui, 2012). It has been reported (Behr et al, 2000;Boswell and Brechbiel, 2005) that Auger emitters (I-125, In-111) may exhibit better therapeutic effect, when bound to an internalizing monoclonal antibody, than β À -emitters (I-131, Y-90) which have been used successfully in the treatment of non-Hodgkins' lymphoma Pouget et al, 2011;Song and Sgouros, 2011).…”